Kyle Faget Describes Expectations, Concerns for Medical Technology in 2025
Foley & Lardner LLP partner Kyle Faget is quoted in two Medtech Insight articles on key challenges the industry is facing in the year ahead.
In the article, “Medtech 2025: Deregulation, Tariffs Anticipated From New US Administration,” Faget described the impact a new Secretary of the Department of Health and Human Services may have, specifically on vaccinations, and in particular, COVID vaccinations. “There has been a lot of clinical trial follow up to assess ongoing safety and efficacy issue of the COVID vaccine,” Faget noted, “but I wonder if we will see a re-litigation of the vaccine wholesale.
In the second article, “Medtech 2025: ‘Moving Forward, No Matter What,’” Faget commented that a more hands-off approach at the U.S. Food and Drug Administration is likely under the second Trump administration, “which could lead to a lot of unregulated or underregulated AI in health care.
“I think we will see explosive innovation in this space, but I am concerned that lack of strict regulatory oversight could lead to safety and efficacy issues,” Faget added.
